Trevi Therapeutics, Inc.
TRVI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001563880
In the last 90 days, Trevi Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 218 institutions reported holding it in 13F filings for Q2 2026, worth $2.76B in total; Viking Global Investors is the only superinvestor holding it.
Holders of 5% or more of TRVI
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Trevi Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| New Enterprise Associates 16, L.P. | 13D/A | 11.60%15.1M shares | −0.40 ppfrom 12.00% | Mar 20, 20253 filings | Feb 13, 2026 | SEC |
| Frazier Life Sciences Public Fund, L.P. | 13G/A | 7.00%8.51M shares | −3.60 ppfrom 10.60% | Feb 14, 20253 filings | Nov 14, 2025 | SEC |
| BlackRock, Inc. | 13G | 5.60%6.80M shares | New | Oct 17, 20251 filing | Oct 17, 2025 | SEC |
| FMR LLC | 13G | 5.10%6.50M shares | New | Feb 5, 20261 filing | Feb 5, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
19 Schedule 13D and 13G filings on Trevi Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Mar 27, 20261:31 PM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | −5.01 ppfrom 5.01%Below 5% | Mar 13, 2026 | SEC |
| Feb 13, 20264:26 PM ET | Rubric Capital Management LPand 1 other | 13G/A | 2.94%3.77M shares | −4.18 ppfrom 7.12%Below 5% | Dec 31, 2025 | SEC |
| Feb 13, 20264:05 PM ET | New Enterprise Associates 16, L.P.and 12 others | 13D/A | 11.60%15.1M shares | −0.40 ppfrom 12.00% | Aug 7, 2025 | SEC |
| Feb 5, 20261:40 PM ET | FMR LLCand 1 other | 13G | 5.10%6.50M shares | New | Dec 31, 2025 | SEC |
| Jan 30, 20262:43 PM ET | Vanguard Group Inc | 13G | 5.01%6.43M shares | New | Dec 31, 2025 | SEC |
| Nov 14, 20254:55 PM ET | Viking Global Investors LPand 10 othersSuperinvestorViking Global Investors | 13G/A | 4.20%5.13M shares | −1.70 ppfrom 5.90%Below 5% | Sep 30, 2025 | SEC |
| Nov 14, 20254:29 PM ET | Frazier Life Sciences Public Fund, L.P.and 13 others | 13G/A | 7.00%8.51M shares | −3.60 ppfrom 10.60% | Sep 30, 2025 | SEC |
| Oct 17, 20256:24 PM ET | BlackRock, Inc. | 13G | 5.60%6.80M shares | New | Sep 30, 2025 | SEC |
| Aug 14, 20255:35 PM ET | Viking Global Investors LPand 10 othersSuperinvestorViking Global Investors | 13G/A | 5.90%7.51M shares | −2.80 ppfrom 8.70% | Jun 30, 2025 | SEC |
| Aug 11, 20256:56 PM ET | New Enterprise Associates 16, L.P.and 12 others | 13D/A | 12.00%15.1M shares | −3.00 ppfrom 15.00% | Aug 7, 2025 | SEC |
| Jul 9, 20254:06 PM ET | Rubric Capital Management LPand 1 other | 13G | 7.12%8.53M shares | +2.41 ppfrom 4.71% | Jun 30, 2025 | SEC |
| May 15, 20254:34 PM ET | Viking Global Investors LPand 10 othersSuperinvestorViking Global Investors | 13G/A | 8.70%9.19M shares | – | Mar 31, 2025 | SEC |
| May 15, 20259:55 AM ET | Frazier Life Sciences Public Fund, L.P.and 13 others | 13G/A | 10.60%10.3M shares | −1.30 ppfrom 11.90% | Mar 31, 2025 | SEC |
| Mar 20, 20257:55 PM ET | New Enterprise Associates 16, L.P.and 12 others | 13D/A | 15.00%15.1M shares | – | Mar 18, 2025 | SEC |
| Feb 14, 20256:04 PM ET | Venrock Healthcare Capital Partners II, L.P.and 9 others | 13G/A | 1.40%1.27M shares | –Below 5% | Dec 31, 2024 | SEC |
| Feb 14, 202511:21 AM ET | Frazier Life Sciences Public Fund, L.P.and 13 others | 13G/A | 11.90%10.7M shares | – | Dec 31, 2024 | SEC |
| Feb 13, 20254:01 PM ET | Rubric Capital Management LPand 1 other | 13G/A | 4.71%4.21M shares | –Below 5% | Dec 31, 2024 | SEC |
| Feb 13, 20251:41 PM ET | Rosalind Advisors, Inc.and 3 others | 13G/A | 1.20%1.06M shares | –Below 5% | Feb 13, 2025 | SEC |
| Jul 10, 20244:16 PM ET | MAI Capital Management | 13G/A | 2.20%1.52M shares | –Below 5% | May 12, 2022 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Trevi Therapeutics, Inc. shares.
No Form 144 notices for Trevi Therapeutics, Inc. are on file.